Page last updated: 2024-10-24

negative regulation of growth hormone secretion

Definition

Target type: biologicalprocess

Any process that decreases or stops the frequency, rate or extent of the regulated release of growth hormone from a cell. [GOC:dph]

Negative regulation of growth hormone secretion is a complex process that involves multiple regulatory pathways and feedback loops. It ensures that growth hormone (GH) production and release are tightly controlled, preventing excessive growth and maintaining overall homeostasis.

**Hypothalamic-Pituitary Axis:**
The primary regulatory mechanism for GH secretion involves the hypothalamic-pituitary axis. The hypothalamus, located in the brain, produces two key hormones that regulate GH release from the pituitary gland:
- **Growth hormone-releasing hormone (GHRH):** Stimulates GH synthesis and release from the anterior pituitary gland.
- **Somatostatin:** Inhibits GH release from the anterior pituitary gland.

**Feedback Mechanisms:**
- **Negative feedback by GH:** GH itself acts as a negative regulator, inhibiting the release of GHRH from the hypothalamus and suppressing its own production by the pituitary gland. This feedback loop helps maintain appropriate GH levels.
- **Negative feedback by insulin-like growth factor 1 (IGF-1):** IGF-1, a hormone produced in response to GH action, also exerts negative feedback. IGF-1 directly inhibits GH release from the pituitary and indirectly suppresses GHRH secretion from the hypothalamus.

**Other Regulatory Factors:**
- **Stress:** Psychological and physical stress can suppress GH secretion.
- **Nutritional status:** Malnutrition or fasting can decrease GH production.
- **Sleep:** Deep sleep stages promote GH release, while sleep deprivation can reduce it.
- **Age:** GH secretion naturally declines with age.
- **Hormones:** Other hormones, including thyroid hormones, cortisol, and sex hormones, can influence GH regulation.

**Molecular Mechanisms:**
The negative regulation of GH secretion involves various molecular mechanisms, including:
- **G protein-coupled receptor signaling:** GHRH and somatostatin bind to their respective G protein-coupled receptors on pituitary cells, triggering intracellular signaling cascades that regulate GH production and release.
- **Gene expression regulation:** Transcription factors and signaling pathways influence the expression of genes involved in GH synthesis and release.
- **Post-translational modifications:** GH undergoes post-translational modifications, such as phosphorylation, that can affect its stability and secretion.

**Consequences of Dysregulation:**
Disruption of negative regulation of GH secretion can lead to various clinical conditions, including:
- **Gigantism:** Excessive GH production during childhood can result in abnormally tall stature.
- **Acromegaly:** Excessive GH production in adulthood can cause thickening of bones and soft tissues.
- **Dwarfism:** Insufficient GH production during childhood can lead to short stature.

**Conclusion:**
Negative regulation of growth hormone secretion is a complex and tightly controlled process that ensures appropriate GH levels throughout life. It involves multiple regulatory pathways and feedback loops, ensuring proper growth and overall homeostasis.'
"

Proteins (1)

ProteinDefinitionTaxonomy
Tyrosine-protein phosphatase non-receptor type 11A tyrosine-protein phosphatase non-receptor type 11 that is encoded in the genome of human. [PRO:DNx, UniProtKB:Q06124]Homo sapiens (human)

Compounds (24)

CompoundDefinitionClassesRoles
glycyrrhetinic acidcyclic terpene ketone;
hydroxy monocarboxylic acid;
pentacyclic triterpenoid
immunomodulator;
plant metabolite
oxanilic acidoxanilic acid: RN given refers to parent cpd; structure
oleanolic acidhydroxy monocarboxylic acid;
pentacyclic triterpenoid
plant metabolite
phosphotyrosineO(4)-phospho-L-tyrosine : A non-proteinogenic L-alpha-amino acid that is L-tyrosine phosphorylated at the phenolic hydroxy group.

Phosphotyrosine: An amino acid that occurs in endogenous proteins. Tyrosine phosphorylation and dephosphorylation plays a role in cellular signal transduction and possibly in cell growth control and carcinogenesis.
L-tyrosine derivative;
non-proteinogenic L-alpha-amino acid;
O(4)-phosphotyrosine
Escherichia coli metabolite;
immunogen
vanadatesvanadate(3-) : A vanadium oxoanion that is a trianion with formula VO4 in which the vanadium is in the +5 oxidation state and is attached to four oxygen atoms.

Vanadates: Oxyvanadium ions in various states of oxidation. They act primarily as ion transport inhibitors due to their inhibition of Na(+)-, K(+)-, and Ca(+)-ATPase transport systems. They also have insulin-like action, positive inotropic action on cardiac ventricular muscle, and other metabolic effects.
trivalent inorganic anion;
vanadium oxoanion
EC 3.1.3.1 (alkaline phosphatase) inhibitor;
EC 3.1.3.16 (phosphoprotein phosphatase) inhibitor;
EC 3.1.3.41 (4-nitrophenylphosphatase) inhibitor;
EC 3.1.3.48 (protein-tyrosine-phosphatase) inhibitor
4-methylumbelliferyl phosphate
maslinic acid(2Alpha,3beta)-2,3-dihydroxyolean-12-en-28-oic acid: from Luehea divaricata and Agrimonia eupatoriadihydroxy monocarboxylic acid;
pentacyclic triterpenoid
anti-inflammatory agent;
antineoplastic agent;
antioxidant;
plant metabolite
nsc-87877NSC-87877: potent Shp2 (nonreceptor protein tyrosine phosphatase) inhibitor; structure in first source
tingenonetingenone: quinonoid triterpene isolated from Euonymus tingens
geniposideterpene glycoside
tanshinonetanshinone: from root of Salvia miltiorrhiza Bunge; RN given refers to tanshinone I; cardioprotective agent and neuroprotective agentabietane diterpenoidanticoronaviral agent
celastrolmonocarboxylic acid;
pentacyclic triterpenoid
anti-inflammatory drug;
antineoplastic agent;
antioxidant;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
Hsp90 inhibitor;
metabolite
cryptotanshinonecryptotanshinone: from Salvia miltiorrhizaabietane diterpenoidanticoronaviral agent
tanshinone ii atashinone IIA: a cardiovascular agent with antineoplastic activity; isolated from Salvia miltiorrhiza; structure in first sourceabietane diterpenoid
nsc-89199estramustine phosphate : A steroid phosphate which is the 17-O-phospho derivative of estramustine.carbamate ester;
organochlorine compound;
steroid phosphate
estramustineestramustine : A carbamate ester obtained by the formal condensation of the hydroxy group of 17beta-estradiol with the carboxy group of bis(2-chloroethyl)carbamic acid.

Estramustine: A nitrogen mustard linked to estradiol, usually as phosphate; used to treat prostatic neoplasms; also has radiation protective properties.
17beta-hydroxy steroid;
carbamate ester;
organochlorine compound
alkylating agent;
antineoplastic agent;
radiation protective agent
genipiniridoid monoterpenoidanti-inflammatory agent;
antioxidant;
apoptosis inhibitor;
cross-linking reagent;
hepatotoxic agent;
uncoupling protein inhibitor
cefsulodincefsulodin : A pyridinium-substituted semi-synthetic, broad-spectrum, cephalosporin antibiotic.

Cefsulodin: A pyridinium-substituted semisynthetic, broad-spectrum antibacterial used especially for Pseudomonas infections in debilitated patients.
cephalosporin;
organosulfonic acid;
primary carboxamide
antibacterial drug
nsc 117199
illudalic acidilludalic acid: isolated from Clitocybe illudens; structure in first source
2-amino-6-chloropurine6-chloroguanine : An organochlorine compound that is 7H-purin-2-amine substituted by a chloro group at position 6.

6-chloroguanine: an antimalarial that inhibits hypoxanthine-guanine-xanthine phosphoribosyltransferase; structure in first source
2-aminopurines;
organochlorine compound
4-(3-(1-adamantyl)-4-hydroxyphenyl)-3-chlorocinnamic acid
Dihydrotanshinone Idihydrotanshinone I: extracted from Radix Salviaeabietane diterpenoidanticoronaviral agent
3-(1-(3-(biphenyl-4-ylamino)-3-oxopropyl)-1h-1,2,3-triazol-4-yl)-6-hydroxy-1-methyl-2-phenyl-1h-indole-5-carboxylic acid3-(1-(3-(biphenyl-4-ylamino)-3-oxopropyl)-1H-1,2,3-triazol-4-yl)-6-hydroxy-1-methyl-2-phenyl-1H-indole-5-carboxylic acid: an SHP2 inhibitor; structure in first source